Edgewise Therapeutics (NASDAQ:EWTX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Edgewise Therapeutics (NASDAQ:EWTX) was downgraded by analysts at
Wall S
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 [Yahoo! Finance]
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules